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1. Introduction
  Diarrhoea is probably the most common problem 
encountered by the farm animals. Other than the dietary 
factors, bacterial, viral or parasitic infection is the main 
causes of diarrhoea in livestock. However, diarrhoeagenic 
Escherichia coli (E.coli) are probably the most common 
pathogen to affect the animals due to its ubiquitous 
existence, easy transmission and its rapidly emerging drug 
resistance property. Our recent reports suggested that 
yak is a potential reservoirs of multidrug resistant STEC 
and EPEC and it is of great public health significance as 
they were isolated from alimentary tract of diarrhoeic 
yak[2] as well as from raw yak milk and milk products[3] 
frequently consumed by the tribal highlanders.   STEC 
and ETEC have also been isolated from faecal samples 
diarrhoeic lambs[4] from the same region, showing their 
existence in various animal species. Very limited studies 
were conducted on the antimicrobial resistance of the 
diarrhoeagenic E. coli in India. Our previous studies 
indicated that many strains of E. coli from diarrhoeic yaks 
exhibited resistance against genatmicin, tetracycline, 
ampicillin, furazolidone, Co-trimoxazole, colistin, 
cephalexin, and nalidixic acid. The better antimicrobial 
agents in terms of sensitivity were norfloxacin and 
cephataxime[1]. However, antimicrobial resistance of STE/
EPEC or ETEC may be transferred via plasmid transfer 
to other sensitive bacteria and they can enter in human 
food chain. Report on rapid emergence of resistance 
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against the frontline and conventional remedies[1, 5]
among other pathogens in yaks like Moraxella bovis, 
Neisseria, Mycobacterium is a grave concern now-a-
days. Therefore, a safe, novel, cost-effective, alternative 
therapeutic strategy especially from herbal origin is the 
need of the hour. Some of the plant derived products 
were recorded to be effective against many of the multi-
drug resistant bacterial pathogens in yaks[6]. However, 
such trials were not made against enterotoxigenic or Shiga 
toxin producing E. coli strains despite their resistance 
against various antimicrobials. Berberine is a plant derived 
quaternary ammonium salt from the protoberberine group 
of isoquinoline alkaloids, with a long history of medicinal 
use in both Ayurvedic and Chinese medicine. It is generally 
found in the roots, rhizomes, and stem bark of varieties of 
medicinal plants like Berberis aquifolium (Oregon grape), 
Berberis vulgaris (Barberry), and Berberis aristata (Tree 
Turmeric), Hydrastis canadensis (Goldenseal), Phellodendron 
amurense (Amur Cork Tree), Coptis chinensis (Chinese 
Goldthread), Tinospora cordifolia (Guduchi)[7-8]. Literatures 
regarding the antimicrobial efficacy of berberine are scarcely 
available. Therefore, the present study was conducted to 
determine the antimicrobial potency of berberine against 
drug resistant E. coli.
2. Materials and methods
2.1. Chemicals
  All the chemicals & reagents used in the present study 
were obtained from Sigma Chemicals, USA, E-Merk, India, 
Hi-Media, Mumbai, India and SRL, India.
2.2. Experimental design
  In order to carry out the antibacterial effect of berberine, 
five multi-drug resistant (MDR) STEC/EPEC and five MDR 
ETEC strains isolated from yaks with haemorrhagic diarrhoea 
were selceted. All these enterovirulent E. coli isolates were 
resistant to more than six drugs investigated in the present 
study and representatives of diverse serogroups.
2.3. Determination of antibacterial activity by broth dilution 
method
  Broth dilution assay was performed as stated earlier by 
the author[5]. Briefly, sterile tubes containing 10 mL of 
trypticase soy broth or MH broth (Hi Media, Mumbai) were 
supplemented with different concentrations of serially 
diluted berberine chloride (0-10 毺M). The tubes were 
inoculated separately with multi-drug resistant strains of 
enterovirulent E. coli isolates at concentrations of 1.5 × 106/mL
- 3 × 106/mL respectively. The initial OD (optical density) 
was observed at 650 nm. Following incubation for 24 h, again 
the OD650 was observed. The viability of the organisms was 
calculated in terms of turbidity and the difference between 
final OD650 and the initial OD650 (Specific OD650) is interpreted 
as the growth of the bacteria. The viability of bacteria at 
any specific concentration was calculated as the percentage 
of specific OD650 at that concentration versus the specific 
OD650 of the tube without berberine supplementation 
(negative control). The calculation can be shown as follows
Percent viable =
Specific OD650 (Final OD650 - Initial OD650)  for any 
concentration of berberine × 100
Specific OD650 (Final OD650-Initial OD650) of the negative 
control (berberine)
For each concentration of berberine, equal amount of DMSO 
was added to each tube to exclude out the bactericidal effect 
of the vehicle, if any.
2.4. Determination of antibacterial activity by disc diffusion 
method
  Disc diffusion method was employed following the 
recommendations of the CLSI, 2008 as described elsewhere[5]. 
Sterile disc (Hi Media, Mumbai) were impregnated with each
of the berberine solution (200 mg/mL) to get the desired 
concentration (0-10 毺M), and dried in laminar flow cabinet. 
Following spreading the bacterial inoculums (Resistant 
strains of enterovirulent E. coli as stated above) evenly over 
the surface of Muller Hinton agar plates, the impregnated 
discs were positioned and incubated at 37 曟 for 24 h.  Sterile 
disc was used as negative control. The antibacterial activity 
was interpreted from the size of the zone of inhibition.
2.5. Determination of binding kinetics of berberine to DNA 
and protein
  The binding kinetics of berberine was determined by 
the earlier described protocol of Jian-ling et al. with little 
modification[9]. Briefly, 50 mg of Salmon sperm DNA, and 
BSA (Procured from Sigma, USA) was dissolved in 500 毺L
PBS buffer (0.02 mol/L, pH 7.0), containing various 
concentrations of berberine (25, 50, 75, 100, 150, 200, 250, 
300, 400, and 500 毺g/mL). The control group contained 
only berberine for each concentration. The mixture was 
incubated at 37 曟 at room temperature for 1 h. Following 
this 1.2 volumes of isopropanol and 1.2 volumes of 80% 
(NH4)2SO4 were added into the tubes containing DNA and BSA 
respectively, and stored at 4 曟 for 1 h. Finally the mixture 
and control tubes were centrifuged at 13 000 r/min for 30 min.
The supernatants were transferred into new tubes, and 
the deposits were collected and dried. Afterwards, the 
absorbance of the supernatants was measured by UV- 
Spectrophotometer (Shimadzu) at 370 nM, and defined as 
Ad (the remainder berberine). The A370 of the control group 
was defined as Ac. The amount of bound berberine (Ab) 
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was calculated by the equation: Ab = Ac× Ad. The binding 
kinetic curves were plotted using the software GraphPad 
Prism 5, with the X axis of berberine concentration and Y 
axis of the absorbance value. The kinetic parameters were 
given by one site binding (hyperbola) equation of the same 
software and Bmax and Kd were determined accordingly.  
3. Results
3.1. Determination of minimal inhibitory concentration by 
broth dilution method
  The antibacterial effect of berberine on different MDR 
STEC/EPEC and ETEC isolates (Table 1) is depicted in Figure 
1 and 2. For both categories of enterovirulent E. coli isolates, 
berberine displayed the antibacterial effect in a dose 
dependent manner. There was no distinct variability among 
these strains in terms of their susceptibility to berberine. At 
a concentration of 1 毺M, berberine decreased the viability 
of the MDR STEC/EPEC strains to 65%-77% and at 5 毺M 
the viability was decreased to 19%-36%. At a concentration 
of 7.5 毺M viability of the MDR STEC/EPEC strains was 
decreased significantly to 0-11%. The viability pattern of 
the MDR ETEC strains is illustrated in Figure 2. At 1 毺M
concentration of berberine hydrochloride, the viability of 
the ETEC strains were decreased to 60%-64% and it was 
further reduced to 19%-26% and 0-7% at 5 毺M and 7.5 毺M 
respectively. The MIC50 of berberine chloride for STEC/EPEC 
isolates varied from 2.07 毺M to 3.6 毺M with a mean of (2.95
依0.33) 毺M where as for ETEC strains it varied from 1.75 毺M
to 1.96 毺M with a mean of (1.87依0.03) 毺M. The MIC80 of 
berberine chloride for STEC/EPEC and ETEC strains were 
(5.82依0.32) 毺M and (5.36依0.14) 毺M, respectively.
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Figure 1. Graphical illustration of antibacterial activity of berberine 
against multi-drug resistant STEC/EPEC isolates from yaks as 
displayed by broth dilution method. 
Y axis shows the viability of the bacteria tested against different 
concentrations of berberine plotted on X axis.
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Figure 2. Graphical illustration of antibacterial activity of berberine 
against multi-drug resistant ETEC isolates from yaks as displayed by 
broth dilution method. 
Y axis shows the viability of the bacteria tested against different 
concentrations of berberine plotted on X axis.
3.2. Determination of antibacterial activity by disc diffusion 
method
  The disc diffusion assay revealed comparable zones of 
inhibition with berbeine at 24h of incubation. Antibacterial 
activity of berberine against multi-drug resistant 
enterovirulent E. coli isolate from yaks showed the isolate 
displayed a clear and large zone of inhibition against 
berberine impregnated disc (B; 10 毺M). However, it was 
completely resistant to Norfloxacin (Nx;10 毺G) A sterile disc 
impregnated with same amount of dimethyl sulphoxide (S) 
was also kept as vehicle control. 
  Vehicle control discs or antibiotic control discs had no 
observable effect on the bacterial growth. Against both 
categories of MDR isolates berberine reduced the growth 
conspicuously. However, distinct variation was observed 
between the susceptibility of STEC/EPEC and ETEC. At a 
concentration of 2.5 毺M zone of inhibition of the STEC/
EPEC isolates was (2.2依0.25) 毺M. At the same concentration, 
the zone of inhibition was markedly higher (3.9依0.43 毺M)
in ETEC isolates. Similarly at higher concentrations of 
berberine i.e. 5 and 10 毺M, the zones of inhibition of ETEC 
isolates (6.6依 0.4 mM; 9.6依0.8 mM) were much higher than 
that of the STEC/EPEC isolates (7.3依0.46 mM; 15.2依0.9 mM). 
The results were quite in parallel with that of the broth 
dilution methods where, MDR ETEC isolates showed more 
sensitivity than that of the STEC/EPEC isolates to berberine 
hydrochloride. Nevertheless, in both the methods berberine 
displayed clear antibacterial activity against MDR STEC/
EPEC and ETEC isolates.
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3.3. Determination of DNA and protein binding kinetics of 
berberine chloride
  DNA and protein binding kinetics of berberine were 
computed in Graph pad prism (Figure 3, 4) and it clearly 
indicated that berberine chloride bind more tightly with 
double helix DNA with Bmax (maximum number of binding 
sites) and Kd (ligand concentration that binds to half the 
receptor sites at equilibrium) of [(24.68依2.62) 毺M and (357.8
依57.8) 毺M], respectively[R2; 0.98]. With protein berberine 
reacted comparatively in loose manner with Bmax and Kd 
of [(18.9依3.83) 毺M and (286.2依113.6) 毺M], respectively[R2; 
0.93].
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Figure 3. Graphical illustration of DNA binding kinetics of berberine 
chloride.
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Figure 4. Graphical illustration of protein binding kinetics of 
berberine chloride.
4. Discussion
  The antibacterial activity of berberine as observed in the 
present study can be attributed to its strong binding to the 
nucleic acid. This is in corroboration with the previous 
findings of[6]. Berberine extracts and decoctions have 
demonstrated significant antimicrobial activity against 
a variety of organisms including bacteria, viruses, fungi, 
protozoans, helminths, and chlamydia[7-8]. Previously, 
antimicrobial property of berberine was reported in several 
experimental models[10-11]. Berberine containing plants 
- Berberis vulgaris and Hydrastis canadensis are used in 
homeopathic medicine for treatment of nephrolithiasis, back 
pain, urogenital infection and gastrointestinal problems. 
In traditional Indian Ayurveda, Chinese and Tibetan 
Table 1
Details of antimicrobial resistance profile of multi-drug resistant STEC/EPEC and ETEC isolates from yaks.
Sl No Isolates used Serogroups Antimicrobial resistance*
1 STEC/EPEC1 O5 Ak, Am, CH,  Cj, Co, E, Fz, G, K,  N, Na, Nf, S
2 STEC/EPEC2 O28 Ak, AT, Ce, CH, Ci, Cj, CPT, CU, E, Fz, G,K, N, Nf, Nx, O, Pf, PT, S
3 STEC/EPEC3 O60 Ac, Ak, Am, AT, Ax, CA, Cj, E, Fz, K, Na, Nf, S
4 STEC/EPEC4 O147 Ac,Ax, AT,CA,Cf, CH,Cj, Do,E, Fz,G, K, Na,Nf, Nx,O, Pf
5 STEC/EPEC5 O172 AT, CH, E, Nf, S 
6 ETEC1 O8 Ac, Ak, Am, AT, E, N, Na, Nf, O, S, T
7 ETEC2 O55 CH, Do, E, Fz, K, Na, Nf, T
8 ETEC3 O110 Am, AT, Ax, Cl, Co, Fz, K, N, Na, S
9 ETEC4 O141 Ak, Am, CA, Do, E, Fz, K
10 ETEC5 O159 AK, AT, Ce, CH, Cj, E, Fz, N, Na, Nf, O, S, T
*Ac (Amoxicillin+Clavulanic acid, 30 毺g), Ak (amikacin, 30 毺g),  10 毺g), Am (amoxicillin, 25 毺g),  AT (azithromycin, 30 毺g), Ax 
(ampicillin+cloxacillin, CA (ceftazidime, 30 毺g), Ce (cephataxime, 30 毺g), Cf (ciprofloxacin, 5 毺g), CH (cephalothin, 30 毺g), Ci (ceftriaxone, 
30 毺g),  Cj (Cefaclor, 30 毺g), Cl (colistin, 10 毺g), Co (co-trimoxazole, 25 毺g),  CPT  (cefepime +tazobactam, 30+10 毺g),  CU (Cefuroxime, 
30 毺g), Do (doxycycline hydrochloride, 30 毺g), E (erythromycin, 10 毺g), Fz (furazolidone, 50 毺g), G (gentamicin, 10 毺g), K (kanamycin, 30 
毺g), N (neomycin, 30 毺g),  Na (nalidixic acid, 30 毺g), Nf (nitrofurantoin, 300 毺g), Nx (norfloxacin, 10 毺g), O (oxytetracycline,  30 毺g), Pf 
(pefloxacin, 5 毺g), PT (piperacillin+tazobactam, 100+10 毺g), S (streptomycin, 30 毺g), T (tetracycline, 30 毺g).
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medicine, berberine extract and decoction was known for 
its efficacy against recurrent and obstinate infection and 
fever[8, 12]. Current studies showed promising results using 
berberine in type II diabetes[13], hypercholesterolemia, 
atherosclerosis[14], congestive heart failure[8, 12, 15], benign 
and malignant carcinoma[16] by clinical and experimental 
studies. Moreover, as a traditional medicine or dietary 
supplement, berberine has shown some activity against 
Alzheimer’s disease[17], methicillin resistant Staphylococcus 
aureus[11], fungal infections, Candida albicans, yeast, 
parasites, and other bacterial/viral infections[9, 11]. The 
present investigation also indicated to its strong interaction 
to nucleic acid. Earlier also, potential nucleic acid-
binding property of berberine was reported[18]. Anticancer 
and antibacterial activity of berberine might be probably 
due to its intercalation with nucleic acid inhibiting the 
multiplication of cells as also evident in this study by its 
DNA and protein binding kinetics. Use of berberine or other 
alternative drugs against STEC infection is more important 
and convincing as therapeutic application of conventional 
antibiotics like gentamicin, cefotaxime and ampicillin was 
reported to increase Shiga toxin release from the bacteria 
thus complicating the condition of the patients[19,20].
  Therefore, it may be concluded that berberine may be used 
as an effective antimicrobial agent against drug resistant 
E. coli, although a large-scale clinical trial is required to 
determine its therapeutic efficacy in vivo. Further, trials 
can be conducted to assess the antimicrobial efficacy of 
berberine hydrochloride against other multi drug resistant 
enteropathogens causing severe economic losses in animal 
husbandry.
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